Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cytomx Thera (CTMX)

Cytomx Thera (CTMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 127,787
  • Shares Outstanding, K 77,919
  • Annual Sales, $ 101,210 K
  • Annual Income, $ -570 K
  • 60-Month Beta 1.14
  • Price/Sales 1.29
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CTMX with:

Options Overview Details

View History
  • Implied Volatility 107.59% ( +38.48%)
  • Historical Volatility 396.57%
  • IV Percentile 16%
  • IV Rank 7.23%
  • IV High 1,127.83% on 09/19/23
  • IV Low 28.02% on 06/21/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 272
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 23,190
  • Open Int (30-Day) 36,758

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.07
  • Number of Estimates 5
  • High Estimate 0.16
  • Low Estimate -0.25
  • Prior Year -0.02
  • Growth Rate Est. (year over year) -250.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5800 +3.16%
on 06/06/24
2.0100 -18.91%
on 05/16/24
-0.3500 (-17.68%)
since 05/10/24
3-Month
1.5800 +3.16%
on 06/06/24
5.8500 -72.14%
on 05/01/24
-0.8700 (-34.80%)
since 03/08/24
52-Week
1.0400 +56.73%
on 10/30/23
5.8500 -72.14%
on 05/01/24
-0.0500 (-2.98%)
since 06/09/23

Most Recent Stories

More News
Biotech Innovations Drive Pancreatic Cancer Treatment: Market Expected to Reach $7.4 Billion by 2032

USA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer patients by focusing on earlier detection. According to Johns Hopkins...

ONCY : 1.0200 (-2.86%)
ONC.TO : 1.42 (-1.39%)
VSTM : 3.32 (-2.35%)
CTMX : 1.6300 (-0.61%)
BNTX : 97.98 (-2.35%)
FGEN : 1.1300 (+2.73%)
Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates

/CNW/ -- USA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer patients by...

ONCY : 1.0200 (-2.86%)
VSTM : 3.32 (-2.35%)
CTMX : 1.6300 (-0.61%)
BNTX : 97.98 (-2.35%)
FGEN : 1.1300 (+2.73%)
ONC.TO : 1.42 (-1.39%)
Stocks Set to Open Higher as Investors Await Key U.S. Inflation Data and Fed Speak

June S&P 500 E-Mini futures (ESM24) are up +0.12%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.25% this morning as trading resumed after the Memorial Day holiday, with investors looking ahead...

ESM24 : 5,365.25 (-0.11%)
NQM24 : 19,088.50 (-0.11%)
DECK : 1,054.95 (+1.02%)
ROST : 144.76 (+0.34%)
AAPL : 193.12 (-1.91%)
WDAY : 212.73 (-1.31%)
INTU : 567.24 (-1.16%)
CRM : 241.84 (unch)
DKS : 216.22 (-1.29%)
CHWY : 22.68 (-0.31%)
HPQ : 36.18 (-0.74%)
AI : 31.36 (+4.53%)
Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection

/CNW/ -- USA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently claimed that a blood test can...

ONCY : 1.0200 (-2.86%)
CADL : 7.03 (-1.68%)
ABVC : 0.7990 (+2.83%)
CTMX : 1.6300 (-0.61%)
AMGN : 304.72 (-0.10%)
ONC.TO : 1.42 (-1.39%)
Biotech Innovations Drive Hope in Global Fight Against Pancreatic Cancer

USA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently claimed that a blood test can accurately detect early-stage pancreatic cancer with...

ONCY : 1.0200 (-2.86%)
ONC.TO : 1.42 (-1.39%)
CADL : 7.03 (-1.68%)
ABVC : 0.7990 (+2.83%)
CTMX : 1.6300 (-0.61%)
AMGN : 304.72 (-0.10%)
CytomX Therapeutics: Q1 Earnings Snapshot

CytomX Therapeutics: Q1 Earnings Snapshot

CTMX : 1.6300 (-0.61%)
Stocks Set to Open Higher as Investors Await More Corporate Earnings and Fed Speak

June S&P 500 E-Mini futures (ESM24) are up +0.24%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.18% this morning as market participants looked ahead to a fresh batch of corporate earnings reports...

ESM24 : 5,365.25 (-0.11%)
NQM24 : 19,088.50 (-0.11%)
AMGN : 304.72 (-0.10%)
AAPL : 193.12 (-1.91%)
ANET : 297.58 (+0.27%)
EXPE : 123.38 (+0.26%)
DIS : 102.74 (+1.18%)
TSN : 55.95 (+0.16%)
VRTX : 483.28 (+0.05%)
PLTR : 23.13 (-0.77%)
DDOG : 112.99 (+3.22%)
EA : 136.21 (-0.45%)
CytomX Therapeutics: Q3 Earnings Snapshot

CytomX Therapeutics: Q3 Earnings Snapshot

CTMX : 1.6300 (-0.61%)
CytomX Therapeutics: Q2 Earnings Snapshot

CytomX Therapeutics: Q2 Earnings Snapshot

CTMX : 1.6300 (-0.61%)
CytomX Therapeutics (CTMX) Reports Q1 Loss, Tops Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 68.75% and 5.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

CTMX : 1.6300 (-0.61%)
AGLE : 12.01 (+8.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 1.7567
2nd Resistance Point 1.7233
1st Resistance Point 1.6767
Last Price 1.6300
1st Support Level 1.5967
2nd Support Level 1.5633
3rd Support Level 1.5167

See More

52-Week High 5.8500
Fibonacci 61.8% 4.0126
Fibonacci 50% 3.4450
Fibonacci 38.2% 2.8774
Last Price 1.6300
52-Week Low 1.0400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar